Syndax Pharmaceuticals (NASDAQ:SNDX) Share Price Breaks Below 50 Day Moving Average – Time to Sell?

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) crossed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $19.33 and traded as low as $18.05. Syndax Pharmaceuticals shares last traded at $18.22, with a volume of 1,431,512 shares changing hands.

Syndax Pharmaceuticals News Summary

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and still projects Syndax could become profitable beginning in fiscal 2028, with estimated EPS rising to $2.39 by fiscal 2030. However, those forecasts were reduced substantially. Syndax Pharmaceuticals stock information
• Neutral Sentiment: Syndax granted inducement stock options covering up to 213,300 shares to nine new employees. The awards support hiring and retention but could create modest future share dilution. Syndax Pharmaceuticals reports inducement grants
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across the outlook: Q3 2026 to a loss of $0.53 from $0.48, Q4 to a loss of $0.50 from $0.40, and full-year 2026 to a loss of $2.07 from $1.92. Longer-term estimates were also reduced, including fiscal 2027 to a loss of $0.79 from $0.41, fiscal 2028 to $0.10 from $0.84, fiscal 2029 to $1.53 from $2.28, and fiscal 2030 to $2.39 from $3.16. The revisions imply slower earnings improvement and likely contributed to the pressure on SNDX. Syndax Pharmaceuticals analyst information
• Negative Sentiment: The stock also crossed below its 50-day moving average, a technical signal that can reinforce near-term selling pressure and weaken investor sentiment. Syndax Pharmaceuticals stock crosses below 50-day moving average

Analysts Set New Price Targets

Several research firms have commented on SNDX. UBS Group reissued a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Thursday. Weiss Ratings downgraded Syndax Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th. Jefferies Financial Group reissued a “buy” rating and set a $35.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday. HC Wainwright reissued a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Thursday. Finally, JPMorgan Chase & Co. reduced their target price on Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $41.80.

Syndax Pharmaceuticals Price Performance

The firm has a market cap of $1.56 billion, a P/E ratio of -7.01 and a beta of 0.42. The stock’s 50-day moving average is $19.27 and its 200-day moving average is $20.78. The company has a quick ratio of 6.44, a current ratio of 6.77 and a debt-to-equity ratio of 38.95.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.10). Syndax Pharmaceuticals had a negative net margin of 87.52% and a negative return on equity of 372.94%. The company had revenue of $72.79 million during the quarter, compared to the consensus estimate of $79.36 million. During the same period last year, the company earned ($0.83) earnings per share. Syndax Pharmaceuticals’s revenue for the quarter was up 91.8% on a year-over-year basis. As a group, equities analysts anticipate that Syndax Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Insider Transactions at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CEO Michael Metzger sold 32,375 shares of the company’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $24.24, for a total value of $784,770.00. Following the completion of the transaction, the chief executive officer owned 484,843 shares of the company’s stock, valued at $11,752,594.32. This represents a 6.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 4.80% of the stock is owned by corporate insiders.

Institutional Trading of Syndax Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of SNDX. Allworth Financial LP bought a new stake in Syndax Pharmaceuticals in the second quarter valued at about $26,000. Nykredit A S acquired a new position in Syndax Pharmaceuticals in the second quarter worth about $72,000. Integrated Wealth Concepts LLC bought a new position in Syndax Pharmaceuticals during the second quarter worth about $73,000. Allianz Asset Management GmbH bought a new position in Syndax Pharmaceuticals during the second quarter worth about $203,000. Finally, Pallas Capital Advisors LLC acquired a new stake in Syndax Pharmaceuticals during the second quarter valued at approximately $207,000.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research programs target biological pathways involved in malignancy and immune-related conditions, with an emphasis on medicines that may address significant unmet medical needs.

Syndax’s lead product, Revuforj (revumenib), is an oral menin inhibitor approved by the U.S. Food and Drug Administration for treating relapsed or refractory acute leukemia with a KMT2A translocation in adults and pediatric patients aged one year and older.